Differential Effects of Statins (Pravastatin or Simvastatin) on Ventricular Ectopic Complexes: Gαi2, a Possible Molecular Marker for Ventricular Irritability

American Journal of Cardiology

Volumn 105, Issue 8, 2010, Pages 1112-1117

  Welzig, C Michael ^c   Park, Ho Jin ^a   Naggar, Jack ^a   Confalone, Deborah ^b   Rhofiry, Joanne ^a   Shea, Julie ^d   Karas, Richard H ^a,b   Estes III, N A Mark ^b   Galper, Jonas B ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MOLECULAR MARKER; POLYCLONAL ANTIBODY; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR EFFECT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART ARRHYTHMIA; HEART PROTECTION; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; LYMPHOCYTE; MALE; PARASYMPATHETIC FUNCTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RR INTERVAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

ADULT; AGED; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CROSS-OVER STUDIES; DENSITOMETRY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; FOLLOW-UP STUDIES; GTP-BINDING PROTEIN ALPHA SUBUNIT, GI2; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRAVASTATIN; PROGNOSIS; RETROSPECTIVE STUDIES; SIMVASTATIN; TREATMENT OUTCOME; VENTRICULAR PREMATURE COMPLEXES;

EID: 77950367671     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.12.011     Document Type: Article

References (22)

1. Vyas A.K., Guo H., Moss A.J., Olshansky B., McNitt S.A., Hall W.J., Zareba W., Steinberg J.S., Fischer A., Ruskin J., and Andrews M.L. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 47 (2006) 769-733
2. Mitchell L.B., Powell J.L., Gillis A.M., Kehl V., and Hallstrom A.P. Are lipid-lowering drugs also antiarrhythmic drugs?. An analysis of the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 42 (2003) 81-87
3. De Sutter J., Tavernier R., De Buyzere M., Jordaens L., and De Backer G. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol 36 (2000) 766-772
4. Goldberger J.J., Subacius H., Schaechter A., Howard A., Berger R., Shalaby A., Levine J., and Kadish A.H. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 48 (2006) 1228-1233
5. Schwartz P.J., La Rovere M.T., and Vanoli E. Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. Circulation 85 (1992) 177-191
6. Schwartz P.J., and Zipes D.P. Autonomic modulation of cardiac arrhythmias. In: Zipes D.P., and Jalife J. (Eds). Cardiac Electrophysiology: From Cell to Bedside (2000), W. B. Saunders, Philadelphia, Pennsylvania 300-314
7. Kiuchi K., Shannon R.P., Komamura K., Cohen D.J., Bianchi C., Homcy C.J., Vatner S.F., and Vatner D.E. Myocardial beta-adrenergic receptor function during the development of pacing-induced heart failure. J Clin Invest 91 (1993) 907-914
8. Lerman B.M.S., Mittal S., and Iwai S. Ventricular Tachycardia in Structurally Normal Hearts (2004), W. B. Saunders, Philadelphia, Pennsylvania 668-682
9. Welzig C.M., Shin D.G., Park H.J., Kim Y.J., Saul J.P., and Galper J.B. Lipid lowering by pravastatin increases parasympathetic modulation of heart rate: Galpha(i2), a possible molecular marker for parasympathetic responsiveness. Circulation 108 (2003) 2743-2746
10. Hughes A., Rogers M.J., Idris A.I., and Crockett J.C. A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo. Calcif Tissue Int 81 (2007) 403-413
11. Eckernas S.A., Roos B.E., Kvidal P., Eriksson L.O., Block G.A., Neafus R.P., and Haigh J.R. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia. Br J Clin Pharmacol 35 (1993) 284-289
12. Freeman R., Saul J.P., Roberts M.S., Berger R.D., Broadbridge C., and Cohen R.J. Spectral analysis of heart rate in diabetic autonomic neuropathy. A comparison with standard tests of autonomic function. Arch Neurol 48 (1991) 185-190
13. Anderson K.P. Lipid-lowering therapy for prevention of ventricular tachyarrhythmias. J Am Coll Cardiol 42 (2003) 88-92
14. Schwartz P.J., Billman G.E., and Stone H.L. Autonomic mechanisms in ventricular fibrillation induced by myocardial ischemia during exercise in dogs with healed myocardial infarction. An experimental preparation for sudden cardiac death. Circulation 69 (1984) 790-800
15. Cole C.R., Blackstone E.H., Pashkow F.J., Snader C.E., and Lauer M.S. Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med 341 (1999) 1351-1357
16. Cole C.R., Foody J.M., Blackstone E.H., and Lauer M.S. Heart rate recovery after submaximal exercise testing as a predictor of mortality in a cardiovascularly healthy cohort. Ann Intern Med 132 (2000) 552-555
17. Kataoka M., Ito C., Sasaki H., Yamane K., and Kohno N. Low heart rate variability is a risk factor for sudden cardiac death in type 2 diabetes. Diabetes Res Clin Pract 64 (2004) 51-58
18. Donahue J.K., Heldman A.W., Fraser H., McDonald A.D., Miller J.M., Rade J.J., Eschenhagen T., and Marban E. Focal modification of electrical conduction in the heart by viral gene transfer. Nat Med 6 (2000) 1395-1398
19. Haigh L.S., Leatherman G.F., O'Hara D.S., Smith T.W., and Galper J.B. Effects of low density lipoproteins and mevinolin on cholesterol content and muscarinic cholinergic responsiveness in cultured chick atrial cells. Regulation of levels of muscarinic receptors and guanine nucleotide regulatory proteins. J Biol Chem 263 (1988) 15608-15618
20. Liang B.T., Hellmich M.R., Neer E.J., and Galper J.B. Development of muscarinic cholinergic inhibition of adenylate cyclase in embryonic chick heart. Its relationship to changes in the inhibitory guanine nucleotide regulatory protein. J Biol Chem 261 (1986) 9011-9021
21. Eschenhagen T., Mende U., Diederich M., Hertle B., Memmesheimer C., Pohl A., Schmitz W., Scholz H., Steinfath M., Bohm M., Michel M.C., Brodde O.E., and Raap A. Chronic treatment with carbachol sensitizes the myocardium to cAMP-induced arrhythmia. Circulation 93 (1996) 763-771
22. Park H.J., Georgescu S.P., Du C., Madias C., Aronovitz M.J., Welzig C.M., Wang B., Begley U., Zhang Y., Blaustein R.O., Patten R.D., Karas R.H., Van Tol H.H., Osborne T.F., Shimano H., Liao R., Link M.S., and Galper J.B. Parasympathetic response in chick myocytes and mouse heart is controlled by SREBP. J Clin Invest 118 (2008) 259-271